These calculations are typically required for pre-clinical toxicokinetic studies, clinical Phase 1–2 multiple dose studies, and dose range finding studies.
New NCA Ratios and Differences tool in Phoenix WinNonlinĬalculating ratios of PK parameters is a common post-processing step for study reports and interpreting results. This blog post summarizes the key new features and enhancements in Phoenix 8.1-for more detail, watch the webinar. A recent webinar reviewed and demonstrated the innovations made to Phoenix WinNonlin and NLME, and how to get the most out of Phoenix capabilities. And as an ongoing commitment to support compliance and efficiency, many features and functions in our newest version reflect valuable feedback from our Phoenix community. Major enhancements were introduced in the Phoenix workbench last year. Phoenix 8.1, the newest version of Certara’s innovative PK/PD modeling and simulation software used globally by researchers and drug developers in pharma, academia, and regulatory agencies, will be available on June 15, 2018.
0 kommentar(er)
